Agenus Brain Cancer Vaccine Shows Extended Survival in Phase 2 Final Data Analysis

Median Overall Survival Nearly Double than Expected with Standard of Care Alone June 1, 2014 Agenus Inc., announced final results from a single-arm, multi-institutional, open-label, Phase 2 study showing that patients with newly diagnosed glioblastoma multiforme (GBM) who received Agenus’ Prophage autologous cancer vaccine added to the standard of care treatment, lived nearly twice as long as expected. In this Phase …